In this study, we used Inovio’s proprietary SynCon® technology to design a synthetic consensus DNA vaccine targeting CSPG4 (SynCon® CSPG4) and assessed its immunogenicity and preclinical efficacy in a tumor-bearing mouse model of melanoma. The gene discussed is CSPG4; the disease is neoplasm.